MNPR vs. VAXX, GRTX, AEZS, ERNA, KTRA, ABVC, MBRX, AVTX, GHSI, and MTEM
Should you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Vaxxinity (VAXX), Galera Therapeutics (GRTX), Aeterna Zentaris (AEZS), Eterna Therapeutics (ERNA), Kintara Therapeutics (KTRA), ABVC BioPharma (ABVC), Moleculin Biotech (MBRX), Avalo Therapeutics (AVTX), Guardion Health Sciences (GHSI), and Molecular Templates (MTEM). These companies are all part of the "pharmaceutical preparations" industry.
Monopar Therapeutics (NASDAQ:MNPR) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, community ranking, media sentiment, profitability, dividends, risk and institutional ownership.
Monopar Therapeutics has higher earnings, but lower revenue than Vaxxinity. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.
Monopar Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Vaxxinity has a beta of 2.79, meaning that its share price is 179% more volatile than the S&P 500.
1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 83.0% of Vaxxinity shares are held by institutional investors. 41.6% of Monopar Therapeutics shares are held by company insiders. Comparatively, 64.1% of Vaxxinity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Monopar Therapeutics had 5 more articles in the media than Vaxxinity. MarketBeat recorded 5 mentions for Monopar Therapeutics and 0 mentions for Vaxxinity. Monopar Therapeutics' average media sentiment score of 0.75 beat Vaxxinity's score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media.
Monopar Therapeutics' return on equity of -110.42% beat Vaxxinity's return on equity.
Monopar Therapeutics presently has a consensus target price of $2.00, suggesting a potential upside of 222.58%. Vaxxinity has a consensus target price of $7.00, suggesting a potential upside of 8,488.96%. Given Vaxxinity's higher possible upside, analysts plainly believe Vaxxinity is more favorable than Monopar Therapeutics.
Monopar Therapeutics received 34 more outperform votes than Vaxxinity when rated by MarketBeat users. Likewise, 70.91% of users gave Monopar Therapeutics an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote.
Summary
Monopar Therapeutics beats Vaxxinity on 8 of the 15 factors compared between the two stocks.
Get Monopar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monopar Therapeutics Competitors List
Related Companies and Tools
